Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOLARIS: TV-44749 in Adult Patients With Schizophrenia
NCT05693935Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jan 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of TEV-749 in schizophrenia (7 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Positive and Negative Syndrome Scale Total Score at 8 weeks. Started Jan 2023; status: completed.
02
Drugs
TEV-749
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05693935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05693935.